[1]周雁,牟忠卿,张献博,等.贝那鲁肽治疗2型糖尿病患者的疗效和安全性及给药方式研究[J].国际内分泌代谢杂志,2021,41(03):191-195.[doi:10.3760/cma.j.cn121383-20210228-02068]
　Zhou Yan,Mou Zhongqing,Zhang Xianbo,et al.Study on the efficacy, safety and administration of benaluptide in the treatment of patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2021,41(03):191-195.[doi:10.3760/cma.j.cn121383-20210228-02068]
点击复制

贝那鲁肽治疗2型糖尿病患者的疗效和安全性及给药方式研究()
分享到：

《国际内分泌代谢杂志》[ISSN:1673-4157/CN:12-1383/R]

卷:
41
期数:
2021年03期
页码:
191-195
栏目:
论著
出版日期:
2021-05-20

文章信息/Info

Title:
Study on the efficacy, safety and administration of benaluptide in the treatment of patients with type 2 diabetes mellitus
作者:
周雁; 牟忠卿; 张献博; 于冬妮; 丁钐; 刘砺; 郭立新
北京医院内分泌科,国家老年医学中心,中国医学科学院老年医学研究院 100730
Author(s):
Zhou Yan;  Mou Zhongqing;  Zhang Xianbo;  Yu Dongni;  Ding Shan;  Liu Li;  Guo Lixin.
Department of Endocrinology, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, Beijing 100730, China
关键词:
2型糖尿病;  贝那鲁肽;  磺脲类
Keywords:
Type 2 diabetes mellitus;  Benaglutide;  Sulfonylureas
DOI:
10.3760/cma.j.cn121383-20210228-02068
摘要:
目的 对比贝那鲁肽和磺脲类药物治疗2型糖尿病的疗效和安全性,并对持续皮下注射贝那鲁肽进行探索性分析。方法 选取2017年6月至2020年6月在北京医院就诊的单用二甲双胍或以二甲双胍为基础的二联口服药物治疗血糖控制不佳的2型糖尿病患者60例为研究对象(除外二肽基肽酶4抑制剂、磺脲类或非磺脲类促泌剂),30例加用贝那鲁肽(包括餐前皮下注射20例和持续皮下给药10例),30例加用磺脲类药物(格列喹酮或格列美脲或格列齐特缓释片),分析治疗前后两组糖化血红蛋白(HbA1c)、空腹血糖(FPG)、体重较基线的变化,并做两组间HbA1c达标率(HbA1c<7%)、FPG和体重变化的比较,以及低血糖、胃肠道反应发生率的比较。结果 治疗12周后两组HbA1c、FPG较基线均有显著下降(均P<0.001),贝那鲁肽组体重较基线显著下降(P<0.001),磺脲组体重无显著性变化(P=0.520)。贝那鲁肽组与磺脲组HbA1c达标率无显著差异(χ2=0.703,P=0.796)。贝那鲁肽组低血糖发生率显著低于磺脲组(χ2=4.453,P=0.035),胃肠道不良反应显著高于磺脲组(χ2=15.709,P<0.001)。持续皮下注射贝那鲁肽较常规皮下注射胃肠道不良反应的发生率低(P<0.05)。结论 对于二甲双胍控制不佳的2型糖尿病患者,联合贝那鲁肽及磺脲类药物均有明显降糖疗效,贝那鲁肽较磺脲类药物低血糖发生率低,有明显的减重效果,但胃肠道反应发生率更高。持续皮下注射贝那鲁肽具有可行性,并可减少胃肠道反应发生率。
Abstract:
Objective To compare the efficacy and safety of benaluptide and sulfonylureas in the treatment of type 2 diabetes, and to explore the continuous subcutaneous injection of benaluptide.Methods Sixty patients with type 2 diabetes who had poor blood glucose control(treated with metformin alone or metformin-based dual oral medication)from June 2017 to June 2020 in Beijing Hospital were selected. Patients treated with dipeptidyl peptidase 4 inhibitors and sulfonylureas or non-sulfonylureas meglitinide were excluded. Among them, 30 patients were treated with benaglutide(including 20 cases of pre meal subcutaneous injection and 10 cases of continuous subcutaneous injection), and the other 30 patients were treated with sulfonylureas(gliquidone or glimepiride or gliclazide sustained-release tablets). The changes in the two groups of glycosylated hemoglobin(HbA1c), fasting plasma glucose(FPG), and body weight from baseline were analyzed. The HbA1c compliance(HbA1c<7%)rate, changes of FPG and weight, as well as the incidence of hypoglycemia and gastrointestinal side effects between the two groups were compared.Results After 12 weeks of treatment, HbA1c and FPG decreased significantly compared with baseline in both groups(all P<0.001). The body weight of the benaglutide group was significantly lower than that in the baseline(P<0.001), and the body weight of the sulfonylurea group had no significant change(P=0.520). There was no significant difference in HbA1c compliance rate(HbA1c<7%)between the two groups(χ2=0.703, P=0.796). The incidence of hypoglycemia in the benaglutide group was significantly lower than that in the sulfonylurea group(χ2=4.453, P=0.035), and the gastrointestinal side effects were significantly higher than those in the sulfonylurea group(χ2=15.709, P<0.001). Continuous subcutaneous injection of benaglutide by insulin pump had a lower incidence of gastrointestinal reactions than conventional subcutaneous injection(P<0.05). Conclusions Benaglutide and sulfonylureas have a good treatment effect on patients with type 2 diabetes who are poorly controlled by metformin. Benaglutide has a lower incidence of hypoglycemia than sulfonylureas, and has a significant weight loss effect, but the incidence of gastrointestinal side effects is higher. Subcutaneous injection of benaglutide with insulin pump is feasible and can reduce the incidence of gastrointestinal side effects.

参考文献/References:

[1] Gerstein HC,Colhoun HM,Dagenais GR,et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes(REWIND):a double-blind,randomised placebo-controlled trial[J].Lancet,2019,394(10193):121-130.DOI:10.1016/S0140-6736(19)31149-3.
[2] Marso SP,Daniels GH,Brown-Frandsen K,et al.Liraglutide and cardiovascular outcomes in type 2 diabetes[J].N Engl J Med,2016,375(4):311-322.DOI:10.1056/NEJMoa1603827.
[3] Simpson SH,Lee J,Choi S,et al.Mortality risk among sulfonylureas:a systematic review and network meta-analysis[J].Lancet Diabetes Endocrinol,2015,3(1):43-51.DOI:10.1016/S2213-8587(14)70213-X.
[4] Marso SP,Baeres FMM,Bain SC,et al.Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure[J].J Am Coll Cardiol,2020,75(10):1128-1141.DOI:10.1016/ j.jacc.2019.12.063.
[5] Vaccaro O,Masulli M,Nicolucci A,et al.Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin(TOSCA.IT):a randomised,multicentre trial[J].Lancet Diabetes Endocrinol,2017,5(11):887-897.DOI:10.1016/S2213-8587(17)30317-0.
[6] Zhang YL,Zhou C,Li XF,et al.Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting:a 3-month,multicentre,observational,retrospective,open-label study[J].Obes Sci Pract,2019,5(4):366-375.DOI:10.1002/osp4.342.
[7] Nauck M,Frid A,Hermansen K,et al.Long-term efficacy and safety comparison of liraglutide,glimepiride and placebo,all in combination with metformin in type 2 diabetes:2-year results from the LEAD-2 study[J].Diabetes Obes Metab,2013,5(3):204-212.DOI:10.1111/dom.12012.
[8] Chen YH,Huang CN,Cho YM,et al.Efficacy and safety of dulaglutide monotherapy compared with glimepiride in East-Asian patients with type 2 diabetes in a multicentre,double-blind,randomized,parallel-arm,active comparator,phase Ⅲ trial[J].Diabetes Obes Metab,2018,20(9):2121-2130.DOI:10.1111/dom.13340.
[9] Gallwitz B,Guzman J,Dotta F,et al.Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure(EUREXA):an open-label,randomised controlled trial[J].Lancet,2012,379(9833):2270-2278.DOI:10.1016/S0140-6736(12)60479-6.
[10] Elliott RM, Morgan LM, Tredger JA,et al.Glucagon-like peptide-1(7-36)amide and glucose-dependent insulinotropic polypeptide secretion in response to nutrient ingestion in man:acute post-prandial and 24-h secretion patterns[J].J Endocrinol,1993,138(1):159-166.DOI:10.1677/joe.0.1380159.
[11] Zander M,Madsbad S,Madsen JL,et al.Effect of 6-week course of glucagon-like peptide 1 on glycaemic control,insulin sensitivity,and beta-cell function in type 2 diabetes:a parallel-group study[J].Lancet,2002,359(9309):824-830.DOI:10.1016/S0140-6736(02)07952-7.
[12] Nauck MA,Petrie JR,Sesti G,et al.A phase 2,randomized,dose-finding study of the novel once-weekly human GLP-1 analog,semaglutide,compared with placebo and open-label liraglutide in patients with type 2 diabetes[J].Diabetes Care,2016,39(2):231-241.DOI:10.2337/dc15-0165.
[13] Yamada Y,Katagiri H,Hamamoto Y,et al.Dose-response,efficacy,and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes(PIONEER 9):a 52-week,phase 2/3a,randomised,controlled trial[J].Lancet Diabetes Endocrinol,2020,8(5):377-391.DOI:10.1016/S2213-8587(20)30075-9.
[14] Torekov SS,Holst JJ,Ehlers MR.Dose response of continuous subcutaneous infusion of recombinant glucagon-like peptide-1 in combination with metformin and sulphonylurea over 12 weeks in patients with type 2 diabetes mellitus[J].Diabetes Obes Metab,2014,16(5):451-456.DOI:10.1111/dom.12240.

相似文献/References:

[1]曾静波,王姮.2型糖尿病与自身免疫反应[J].国际内分泌代谢杂志,2007,(04):259.
[2]朱素君,谢锦桃,刘军,等.二甲双胍：2型糖尿病治疗的基础药[J].国际内分泌代谢杂志,2007,(04):280.
[3]刘艳清 易秋艳 邵加庆.肠道菌群与肥胖和糖尿病的关系[J].国际内分泌代谢杂志,2015,(01):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
　Liu Yanqing,Yi Qiuyan,Shao Jiaqing..Relationship between gut microbiota, obesity and diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):31.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.007]
[4]姚旻 赵爱源 张宏.肠道菌群与2型糖尿病[J].国际内分泌代谢杂志,2015,(01):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
　Yao Min*,Zhao Aiyuan,Zhang Hong..Relationship between gut microbiota and type 2 diabetes[J].International Journal of Endocrinology and Metabolism,2015,(03):35.[doi:DOI：10.3760/cma.j.issn.1673-4157.2015.01.008]
[5]赵丽娟,徐宽枫,杨涛,等.SLC30A8和PTPRD基因多态性与南京地区中老年人群2型糖尿病的相关性研究[J].国际内分泌代谢杂志,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
　Zhao Lijuan*,Xu Kuanfeng,Yang Tao,et al.Relationship between SLC30A8 and PTPRD gene polymorphisms and type 2 diabetes in middle aged and elderly people in Nanjing area[J].International Journal of Endocrinology and Metabolism,2015,(03):145.[doi:10.3760/cma.j.issn.1673-4157.2015.03.001]
[6]王洁,何媛,于珮.糖尿病肾病的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
　Wang Jie*,He Yuan,Yu Pei..Risk factors of diabetic nephropathy[J].International Journal of Endocrinology and Metabolism,2015,(03):153.[doi:10.3760/cma.j.issn.1673-4157.2015.03.003]
[7]刘帅,张萍,方毅,等.2型糖尿病合并无症状冠状动脉钙化的相关危险因素分析[J].国际内分泌代谢杂志,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
　Liu Shuai*,Zhang Ping,Fang Yi,et al.Analysis of the risk factors related with asymptomatic coronary calcification for type 2 diabetic patients[J].International Journal of Endocrinology and Metabolism,2015,(03):158.[doi:10.3760/cma.j.issn.1673-4157.2015.03.004]
[8]徐庆海,马颖,李铁马.2型糖尿病患者高甘油三酯血症-腰围表型与甲状腺功能异常的关系[J].国际内分泌代谢杂志,2015,(04):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
　Xu Qinghai,Ma Ying,Li Tiema..Association of hypertriglyceridaemic-waist phenotype with thyroid dysfunction in patients with type 2 diabetes mellitus[J].International Journal of Endocrinology and Metabolism,2015,(03):222.[doi:10.3760/cma.j.issn.1673-4157.2015.04.002]
[9]潘道延,沈洁,朱筱,等.利格列汀对2型糖尿病大鼠代谢性内毒素血症的影响[J].国际内分泌代谢杂志,2015,(04):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
　Pan Daoyan,Shen Jie,Zhu Xiao,et al.Effects of linagliptin on metabolic endotoxemia in type 2 diabetic rats[J].International Journal of Endocrinology and Metabolism,2015,(03):230.[doi:10.3760/cma.j.issn.1673-4157.2015.04.004]
[10]黄桥,白洁,杜洪泉.一种新的脂肪细胞因子——cartonectin[J].国际内分泌代谢杂志,2015,(04):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]
　Huang Qiao*,Bai Jie,Du Hongquan..A novel adipokine--cartonectin[J].International Journal of Endocrinology and Metabolism,2015,(03):265.[doi:10.3760/cma.j.issn.1673-4157.2015.04.014]

备注/Memo

备注/Memo:
通信作者:郭立新,Email:glx1218@163.com 基金项目:重大疾病新药临床评价技术平台建设(SQ2017ZX090304015)
更新日期/Last Update: 2021-05-20